Latest News
Viking Therapeutics publishes Phase 2 data showing up to 14.7% weight loss with VK2735
12 January 2026 - Biopharmaceutical company Viking Therapeutics Inc (NASDAQ: VKTX) on Monday announced publication of results from its Phase 2 VENTURE trial evaluating VK2735, a dual GLP-1/GIP receptor agonist, in the peer-reviewed journal Obesity. D...
AbbVie licenses PD-1/VEGF bispecific antibody RC148 from RemeGen in multi-billion dollar oncology deal
12 January 2026 - Oncology company AbbVie (NYSE: ABBV) and biopharmaceutical company RemeGen announced on Monday that the companies have entered into an exclusive licensing agreement for the development, manufacturing and commercialisation of RC148, ...
Boston Scientific to acquire Valencia Technologies to expand overactive bladder portfolio
12 January 2026 - Medical technology company Boston Scientific Corporation (NYSE: BSX) announced on Monday that it has entered into a definitive agreement to acquire Valencia Technologies Corporation, a privately held medical technology company focus...
Formosa Pharmaceuticals licenses APP13007 ophthalmic therapy to Samil for South Korea
12 January 2026 - Taiwanese biotechnology company Formosa Pharmaceuticals, Inc. (TWSE: 6838) announced on Monday that it has entered an exclusive licensing agreement with South Korea-based pharmaceutical manufacturer Samil Pharmaceuticals Co., Ltd. (...
NewcelX reports positive biomaterial study results supporting stem cell islet delivery without immune suppression
12 January 2026 - Biotechnology company NewcelX Ltd (Nasdaq: NCEL) on Monday reported positive results from an international collaborative study evaluating advanced biomaterial strategies to support delivery and function of stem cell-derived islets f...